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Background: Prolonged intensive care unit (ICU) and hospital stay after cardiac surgery is vitally important and is influenced by both intraoperative and postoperative factors.
Objectives: This randomized clinical trial study was designed to assess whether vitamin C supplementation could reduce the length of ICU and hospital stay in post-cardiac surgery patients.
Patients and Methods: Two hundred and ninety patients scheduled for adult cardiac surgery including coronary, valve and congenital operations were randomized into two groups: an intervention group, who received 2 g of vitamin C (ascorbic acid) intravenously, immediately before surgery in the operating theatre, followed by 1 g daily oral doses for the first 4 postoperative days; and a placebo group, who received an equal number of identical tablets in the same shape and size.
Results: Hospital length of stay was significantly different between the two groups (10.17 ± 4.63 days in the intervention group vs. 12 ± 4.51 days in the placebo group; P = 0.01), while there was no significant difference in the ICU stay between the groups (3.42 ± 1.06 days in intervention group vs. 3.43 ± 1.09 days in the placebo group; P = 0.88). There were significant differences in the intubation time and the drainage volume in the ICU and the first 24 postoperative hours between the two groups (P for both = 0.003).
Conclusions: Vitamin C can decrease the length of hospital stay, drainage volume in the ICU and in the first 24 postoperative hours, intubation time and some complications in patients after cardiac surgery; perhaps by decreasing inflammatory factors.
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1. BackgroundThe length of stay in the intensive care unit (ICU) is an im-portant issue in contemporary cardiac surgery and in the management of health care resources around the globe, not least given the rise in the ageing population and lon-gevity of high-risk patients (1, 2). Several factors can affect the length of stay in the ICU and hospital such as disease severity, bypass or cross-clamp time, endotracheal intuba-tion time, hemodynamic instability, older age and comor-bidities. Moreover, postoperative bleeding, need for re-operation and postoperative arrhythmias are among the factors having been associated with an increased length of stay in the ICU, followed by a longer hospital stay (3).Recent years have witnessed great strides taken to re-duce complications and improve the outcome of pa-tients by shortening the ICU or hospital length of stay. To that end, therapeutic approaches, especially admin-istration of antioxidants, have been accorded distinc-tive attention. Many studies have shown that vitamin C, deemed the most important antioxidant, may attenuate electrical remodeling, decrease the incidence of postop-
erative atrial fibrillation (AF) (4), alleviate postoperative pain and reduce the incidence of pulmonary morbidity and dysfunction of the other organs (5-8). Postulating that vitamin C supplementation in cardiac surgery pa-tients might reduce the incidence of complications and ICU and hospital length of stay, we conducted the present randomized clinical trial to evaluate the effect of this an-tioxidant on the length of ICU and hospital stay, drainage volume, need for reoperation and some related factors after cardiac surgery.
2. ObjectivesThis randomized clinical trial study was designed to as-sess whether vitamin C supplementation could reduce the length of ICU and hospital stay in post-cardiac sur-gery patients.
3. Patients and MethodsThis randomized, double-blind, placebo-controlled 
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prospective trial was conducted in patients undergoing cardiac surgery in Rajaie Cardiovascular, Medical and Research Center, Tehran, Iran. The study protocol was in accordance with the Helsinki Declaration of the World Medical Association (2000) and was approved by our local ethics committee. Written informed consent was obtained from all the patients. The inclusion criteria comprised age ≥ 18 years with American Society of An-esthesiologists (ASA) physical status class II-III and candi-dacy for coronary artery bypass graft operation (CABG) or simple congenital valvular disease surgery. Patients who died within the first postoperative day and those who had not received adequate doses of drugs according to our protocol were excluded. Also, we excluded the pa-tients were severe complications (cardiac, respiratory or neurological) or emergent operation.
3.1. Randomisation and InterventionsThe study population was randomized one day before surgery to two groups (By using www.randomaizer.org): the intervention (vitamin C supplementation) group and the placebo group. The method of randomization was balanced block with an allocation sequence based on a block size of eight, generated with a computer random-number generator. Both the patients and the hospital staff were blind to the treatment allocation. The patients in the intervention group received 2 g of vitamin C (ascor-bic acid; Darou Pakhsh Co., Tehran, Iran) intravenously, immediately before surgery in the operating theatre, fol-lowed by 1 g daily oral doses of the tablets for the first four postoperative days. The patients in the placebo group re-ceived an equal number of identical tablets. The placebo tablets and ampoules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. Both groups had the same sur-gical premedication and anesthesia protocol as well as surgical access (median sternotomy).Before surgery, basic information such as age, sex and risk factors was collected, and medications were given to all the patients according to their clinical indications. All the patients were monitored in the open heart ICU before their transfer to a ward. Data such as bypass time and cross-clamp time were collected intraoperatively. Addi-tionally, information was gathered in the ICU on the total length of ICU stay, intubation time, drainage volume and presence of some complications (mortality and morbid-ity) defined as death, any infection, any impairment in the renal function and need for reoperation. Finally, the total duration of hospital stay was recorded for every in-dividual.
3.2. Statistical AnalysisThe statistical analyses were performed with SPSS 15 for Windows (SPSS Inc., Chicago, Illinois). P values ≤ 0.05 were considered significant. The data are expressed as mean values ± standard deviation (SD) for the inter-
val and count (%) for the categorical variables. All the variables were tested for normal distribution with the Kolmogorov-Smirnov test. The categorical values were compared using the chi-square test or the Fisher exact test. The mean variables were compared between the two groups using an independent t-test or the Mann-Whitney U test.A binary logistic regression analysis was performed to adjust the confounding factors of ICU and hospital length of stay. These variables included those that had an association of P < 0.05 with hospital and ICU length of stay in the univariate model.
4. ResultsThe study population consisted of 290 patients at a mean age of 55.78 ± 13.72 years (18-85 years). The interven-tion group comprised 113 patients, and the placebo group included 177 patients. The baseline and surgery-related characteristics of the vitamin C supplementation and placebo groups are depicted in Table 1. There were no significant differences between the groups regarding the measured baseline and perioperative characteristics (age, sex, risk factors and surgery type).The intraoperative variables were also compared be-tween the two groups (Table 1). No difference was found in surgery type and on/off-pump CABG between the groups. There was a significant difference in terms of the intuba-tion time between the two groups (11.83 ± 3.91 vs. 14.14 ± 9.52 hours; P = 0.003), whereas the differences between the study groups regarding bypass time and cross-clamp time constituted no statistically significant differences. The drainage volume in the ICU and in the first 24 post-operative hours differed significantly between the inter-vention and placebo groups (P = 0.003). Also importantly, a significant difference existed between the two groups of patients as regards postoperative complications, de-fined as death, any infection and any impairment in the renal function (P = 0.042). Although the rate of need for reoperation was higher in the intervention group, the dif-ference was not statistically significant between the two groups (P = 0.3). Hospital length of stay was significantly different between the two groups, but the difference in ICU length of stay between the studied groups failed to reach statistical significance. The mean ICU length of stay after surgery was 3.42 ± 1.06 days in the vitamin C supplementation group and 3.43 ± 1.09 days in the pla-cebo group (P = 0.88). The mean hospital length of stay was 10.17 ± 4.63 days among the patients in the interven-tion group and 12 ± 4.51 days among those in the placebo group (P = 0.01) (Table 2).The overall incidence rate of postoperative AF in the vitamin C supplementation group was 40 (35.5%), ver-sus 99 (55.9%) in the placebo group (P = 0.001). The lo-gistic regression analysis showed that AF occurrence was not a confounding factor in the length of hospital or ICU stay (Table 3).
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Table 1.  Perioperative, Intraoperative and Postoperative Characteristics of the Patients a,b
Variables Vitamin C (n = 113) Placebo (n = 177) P Value
GenderMale 80 (70.8) 111 (62.7) 0.15Female 33 (29.2) 66 (37.3) 0.15
Age, y 57.28 ± 14.09 54.22 ± 14.39 0.70
HT 52 (49.5) 73 (46.5) 0.63
DM 27 (26.2) 37 (24) 0.69
C/S 18 (17.6) 26 (16.7) 0.83
HLP 10 (38.5) 22 (34.4) 0.71
Surgery typeCABG 57 (50.4) 94 (53.1) 0.44Valvular 30 (26.5) 52 (29) 0.44Mixed 20 (17.6) 22 (12.4) 0.44Congenital 6 (5.3) 9 (5.5) 0.44
OperationOff-pump 12 (11.2) 16 (9.4) 0.62On-pump 95 (88.8) 154 (90.6) 0.62
Reoperation 7 (6.2) 17 (9.6) 0.30
Complicationsc 4 (3.54) 18 (10.2) 0.042
Bypass time, min 97.17 ± 42.62 86.98 ± 37.98 0.06
Cross-clamp time, min 55.93 ± 30.32 50.89 ± 30.84 0.08
Intubation time, h 11.83 ± 3.91 14.14 ± 9.52 0.003
Drainage in the first 24 postoperative hours (cc) 262.21 ± 190.91 348.50 ± 262.17 0.003
Drainage in ICU (cc) 499.55 ± 296.69 577.96 ± 454.44 0.107a Abbreviations: HT, Hypertension; DM, Diabetes Mellitus; C/S, Cigarette smoking; HLP, Hyperlipidaemia; CABG, Coronary Artery Bypass Grafting.b The data are expressed as mean ± SD for the interval and No. (%) for the categorical variables.c Some Complications Including: Death, Impaired Renal Function and Infection.
Table 2.  ICU and Hospital Length of Stay Comparison Between the Two Groups a,b
Variables Vitamin C (n = 113) Placebo (n = 177) P Value
ICU Stay 3.42 ± 1.06 3.43 ± 1.09 0.88
Hospital Stay 10.17 ± 4.63 12 ± 4.51 0.01a Abbreviation: ICU, Intensive Care Unit.b The data are expressed as mean ± SD.
Table 3.  Logistic Regression for Adjusting AF as a Confounding Factor a
Variables B Beta t P Value
Hospital StayIntervention 0.84 0.09 1.50 0.13AF -0.68 -0.74 -1.24 0.21
ICU StayIntervention 0.01 0.006 0.09 0.92AF -0.01 -0.009 -0.14 0.88a Abbreviations: AF, Atrial Fibrillation; ICU, Intensive Care Unit.
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Table 4.  Binary Logistic Regression Analysis of Factors Affecting the Length of ICU Stay a
Variables B Beta t P Value
Intervention 0.011 0.005 0.077 0.93
Bypass Time 0.003 0.095 0.727 0.46
Cross-Clamp Time 0.002 0.044 0.345 0.73
Intubation Time 0.017 0.135 2.085 0.03
Drainage in the First 24 
Postoperative Hours (cc)
0.000 -0.061 -0.444 0.65
Drainage in ICU (cc) 0.001 0.329 2.439 0.01
Drainage Time 0.000 -0.015 -0.239 0.81
Kind of Surgery 0.105 0.072 0.973 0.33
Reoperation 0.013 0.003 0.050 0.96
Complications 0.561 0.152 2.303 0.02a Abbreviation: ICU, Intensive Care Unit.
Table 5.  Binary Logistic Regression Analysis of Factors Affecting the Length of Hospital Stay a
Variables B Beta t P Value
Intervention 0.660 0.067 1.069 0.286
Drainage in ICU (cc) 0.000 0.049 0.738 0.461
Drainage Time -0.011 -0.084 -1.364 0.174
Intubation Time 0.084 0.150 2.327 0.021
Kind of Surgery 1.148 0.181 2.649 0.009
Reoperation -2.155 -0.133 -1.929 0.055
Operation 0.457 0.028 0.441 0.659
Complications 1.524 0.092 1.444 0.150a Abbreviation: ICU, Intensive Care Unit.
Based on the univariate analysis, the intubation time, bypass time, drainage volume in the ICU and in the first 24-hour postoperative period, drainage time, surgery type, need for reoperation and complications had sig-nificant relationships with the length of stay in the ICU. The logistic regression model showed that the intuba-tion time (odds ratio [OR]: 2.08, P = 0.03) and presence of complications (OR: 2.30, P = 0.02) were the independent factors of the ICU length of stay (Table 4).The univariate analysis demonstrated that the drain-age volume in the ICU and in the first 24 postoperative hours, drainage time, kind of surgery, on/off-pump CABG, need for reoperation and presence of complications had significant relationships with the length of hospital stay. The logistic regression model showed that the intuba-tion time (OR: 2.32, P = 0.02) and surgery type (OR: 2.64, P = 0.009) were the independent factors of hospital length of stay (Table 5).
5. DiscussionA significant body of evidence suggests that antioxidant vitamins, especially vitamin C, have an important role in preventing a number of complications after certain op-
erations, including cardiac surgery (4, 8-11). Many studies have demonstrated a strong relationship between the us-age of vitamin C and a reduction in the incidence of post-operative AF (5, 10, 11). Furthermore, the reduce in devel-opment of pulmonary morbidity and organ failure in the early administration of ascorbic acid supplementation may be due to a decrease in inflammatory and oxidative factors (5). The present study was a randomized placebo-controlled trial in which antioxidant vitamin C was given to patients who underwent cardiac surgery to assess the length of ICU and hospital stay as well as some related factors. The two study groups, intervention and placebo, were similar preoperatively: there were no differences between the vitamin C supplementation group and the placebo group in terms of demographic characteristics, cardiovascular risk factors such as age, sex, diabetes mel-litus, hypertension, hyperlipidaemia and cigarette smok-ing and also surgery kind.In the current study, in accordance with previous stud-ies regarding the effect of vitamin C supplementation on patient outcomes after cardiac surgery, we showed that vitamin C led to a decrease in mortality in the ICU, length of hospital stay, postoperative drainage volume, intubation time and some important complications. 
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There was, however, no statistically significant effect on the length of stay in the ICU. Nathens et al. in their ran-domized trial study demonstrated that the early admin-istration of ascorbic acid supplementation shortened ICU length of stay by reducing the duration of mechani-cal ventilation (5), which chimes in with our findings insofar as the intubation time in the vitamin C group was significantly lower than that in the placebo group (11.83 ± 3.91 hours in the vitamin C group vs. 14.14 ± 9.52 hours in the placebo group; P = 0.003). Our univariate analysis showed that some of the peri- and postopera-tive characteristics of the patients were associated with the length of both ICU and hospital stay. The patients who underwent on-pump CABG had a longer ICU and hospital stay than those who underwent off-pump sur-gery. The length of both ICU and hospital stay increased in the patients undergoing mixed surgery (i.e. simulta-neous CABG and valvular surgery) and in those needing reoperation. Furthermore, we observed a trend towards a longer length of ICU and hospital stay in the patients with prolonged bypass time and cross-clamp time in the operating theatre. Our results revealed that the patients' postoperative characteristics exerted a more significant effect on the length of ICU and hospital stay inasmuch as the duration of endotracheal intubation and the vol-ume of drainage in the ICU and in the first 24 postop-erative hours were significantly associated with a longer stay in the ICU or hospital.Our binary logistic regression analysis of the factors affecting the length of both ICU and hospital stay illus-trated that the most important factor in increasing the length of hospital and ICU stay was the intubation time. In addition, a shorter length of ICU and hospital stay was achieved when the cardiac surgical patients were weaned from the mechanical ventilator at the appropriate time. There is some evidence showing that a prolonged intuba-tion time is associated with a greater frequency of com-plications and prolongation of the ICU stay (12-14). Since our results showed that the intubation time was shorter in the patients who received vitamin C, it can be conclud-ed that vitamin C, by extension, can affect the length of stay in hospital. We examined the incidence of AF as an important factor, which can increase the length of hospi-tal and ICU stay in both groups without a significant dif-ference between them. This large, randomized prospec-tive trial in a cohort of cardiac surgery patients suggests benefit from the routine early, prophylactic administra-tion of vitamin C. Also, the lack of adverse effects, coupled with the minimal expense, supports the notion that this supplementation is a reasonable therapeutic interven-tion in cardiac surgery patients. Vitamin C supplemen-tation can decrease some postoperative complications and the length of hospital stay in patients undergoing cardiac surgery (14-17)
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